Solution to the problem of the poor cyclic fatigue resistance of bulk metallic glasses

The recent development of metallic glass-matrix composites represents a particular milestone in engineering materials for structural applications owing to their remarkable combination of strength and toughness. However, metallic glasses are highly susceptible to cyclic fatigue damage, and previous attempts to solve this problem have been largely disappointing. Here, we propose and demonstrate a microstructural design strategy to overcome this limitation by matching the microstructural length scales (of the second phase) to mechanical crack-length scales. Specifically, semisolid processing is used to optimize the volume fraction, morphology, and size of second-phase dendrites to confine any initial deformation (shear banding) to the glassy regions separating dendrite arms having length scales of ≈2 μm, i.e., to less than the critical crack size for failure. Confinement of the damage to such interdendritic regions results in enhancement of fatigue lifetimes and increases the fatigue limit by an order of magnitude, making these “designed” composites as resistant to fatigue damage as high-strength steels and aluminum alloys. These design strategies can be universally applied to any other metallic glass systems

Fracture toughness and crack-resistance curve behavior in metallic glass-matrix composites

Nonlinear-elastic fracture mechanics methods are used to assess the fracture toughness of bulk metallic glass (BMG) composites; results are compared with similar measurements for other monolithic and composite BMG alloys. Mechanistically, plastic shielding gives rise to characteristic resistance-curve behavior where the fracture resistance increases with crack extension. Specifically, confinement of damage by second-phase dendrites is shown to result in enhancement of the toughness by nearly an order of magnitude relative to unreinforced glass

A genetic algorithm for cocyclic hadamard matrices

A genetic algorithm for finding cocyclic Hadamard matrices is described. Though we focus on the case of dihedral groups, the algorithm may be easily extended to cover any group. Some executions and examples are also included, with aid of Mathematica 4.0

Exotic complex Hadamard matrices, and their equivalence

In this paper we use a design theoretical approach to construct new, previously unknown complex Hadamard matrices. Our methods generalize and extend the earlier results of de la Harpe--Jones and Munemasa--Watatani and offer a theoretical explanation for the existence of some sporadic examples of complex Hadamard matrices in the existing literature. As it is increasingly difficult to distinguish inequivalent matrices from each other, we propose a new invariant, the fingerprint of complex Hadamard matrices. As a side result, we refute a conjecture of Koukouvinos et al. on (n-8)x(n-8) minors of real Hadamard matrices.Comment: 10 pages. To appear in Cryptography and Communications: Discrete Structures, Boolean Functions and Sequence

The cohomological reduction method for computing n-dimensional cocyclic matrices

Provided that a cohomological model for $G$ is known, we describe a method for constructing a basis for $n$-cocycles over $G$, from which the whole set of $n$-dimensional $n$-cocyclic matrices over $G$ may be straightforwardly calculated. Focusing in the case $n=2$ (which is of special interest, e.g. for looking for cocyclic Hadamard matrices), this method provides a basis for 2-cocycles in such a way that representative $2$-cocycles are calculated all at once, so that there is no need to distinguish between inflation and transgression 2-cocycles (as it has traditionally been the case until now). When $n>2$, this method provides an uniform way of looking for higher dimensional $n$-cocyclic Hadamard matrices for the first time. We illustrate the method with some examples, for $n=2,3$. In particular, we give some examples of improper 3-dimensional $3$-cocyclic Hadamard matrices.Comment: 17 pages, 0 figure

Characterization of fatigue-induced free volume changes in bulk metallic glass using positron annihilation spectroscopy

Depth-profiled Doppler broadening spectroscopy of positron annihilation on the cyclic fatigue-induced fracture surfaces of three amorphous Zr₄₄Ti₁₁Ni₁₀Cu₁₀Be₂₅ metallic glass specimens reveals the presence of a 30–50 nm layer of increased free volume that is generated by the propagating fatigue crack tip. The presence and character of this fatigue transformation zone is independent of the initial amount of bulk free volume, which was varied by structural relaxation via annealing, and the voids generated in the zone by intense cyclic deformation are distinct from those typical of the bulk.Keywords: fatigue cracks, copper alloys, Doppler broadening, deformation, beryllium alloys, voids (solid), annealing, zirconium alloys, titanium alloys, nickel alloys, metallic glasses, positron annihilatio

Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment

Objectives The objective of this study was to characterize the pharmacokinetics of unbound and total concentrations of daptomycin in infected ICU patients with various degrees of renal impairment. From these results, the probability of attaining antimicrobial efficacy and the risks of toxicity were assessed. Methods Twenty-four ICU patients with various renal functions and requiring treatment of complicated skin and soft-tissue infections, bacteraemia, or endocarditis with daptomycin were recruited. Daptomycin (Cubicin®) at 10 mg/kg was administered every 24 h for patients with creatinine clearance (CLCR) ≥30 mL/min and every 48 h for patients with CLCR <30 mL/min. Total and unbound plasma concentrations and urine concentrations of daptomycin were analysed simultaneously following a population pharmacokinetic approach. Simulations were conducted to estimate the probability of attaining efficacy (unbound AUCu/MIC >40 or >80) or toxicity (Cmin >24.3 mg/L) targets. Results Exposure to unbound daptomycin increased when the renal function decreased, thus increasing the probability of reaching the efficacy targets, but also the risk of toxicity. Modifications of the unbound fraction (fu) of daptomycin did not affect the pharmacokinetics of unbound daptomycin, but did affect the pharmacokinetics of total daptomycin. Conclusions Daptomycin at 10 mg/kg q24h allowed efficacy pharmacokinetic/pharmacodynamic targets for ICU patients with CLCR ≥30 mL/min to be reached. For patients with CLCR <30 mL/min, halving the rate of drug administration, i.e. 10 mg/kg q48h, was sufficient to reach these targets. No adverse events were observed, but the toxicity of the 10 mg/kg q24h dosing regimen should be further assessed, particularly for patients with altered renal function